The

 

Word

 

Is

Getting

 

Out

 

In the News

 

Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

VANCOUVER, B.C. and WARMINSTER, Pa., Feb. 22, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announcedREAD MORE…

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapiesREAD MORE…

Riot Blockchain Enters Definitive Agreement for the Acquisition of 3,800 S9 Bitcoin Miners

CASTLE ROCK, Colo., Feb. 15, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has enteredREAD MORE…

Oncobiologics Reports First Quarter Fiscal Year 2018 Results

CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) today reported financial results and business highlights for its first fiscal quarter ended DecemberREAD MORE…

Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) —  Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,READ MORE…

Auris Medical Announces Extraordinary General Meeting of Shareholders

Zug, Switzerland, February 9, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Oncobiologics Announces Term Extension Of Series A Warrants

CRANBURY, N.J., Feb. 09, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today an extension to the term for exercise of itsREAD MORE…

Arbutus Consolidates HBV Business Around Warminster, PA Site

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, todayREAD MORE…

Sigilon Therapeutics to Present at Upcoming Conferences

CAMBRIDGE, Mass., Feb. 8, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced thatREAD MORE…

Riot Blockchain Participates in Coinsquare Private Placement; Coinsquare Receives CAD $430 Million Post-Money Valuation

CASTLE ROCK, Colo., Feb. 8, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has investedREAD MORE…

Riot Blockchain Enters LOI to Acquire Logical Brokerage Corp

CASTLE ROCK, Colo., Feb. 7, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it hasREAD MORE…

Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine

Zug, Switzerland, February 7, 2018 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needsREAD MORE…

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

SAN FRANCISCO, Feb. 6, 2018​ – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced toplineREAD MORE…

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

MabVax Therapeutics Closes $2.1 Million Private Placement Financing

SAN DIEGO, Feb. 6, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (the “Company”) (Nasdaq: MBVX), a clinical-stage biotechnology company focused on theREAD MORE…

PolarityTE™ Provides Business Updates on Clinical Use of SkinTE™: Regeneration of Full-Thickness Skin

SALT LAKE CITY, Feb. 05, 2018 (GLOBE NEWSWIRE) — PolarityTE, Inc. (NASDAQ:COOL), today announced that initial results from the clinicalREAD MORE…

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT PhaseREAD MORE…

Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering

Zug, Switzerland, January 29, 2018 – Auris Medical Holding AG (“Auris Medical”, NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmetREAD MORE…

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on January 16, 2018 the Compensation CommitteeREAD MORE…

Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel’s leading commercial partner for innovativeREAD MORE…

Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference

BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stageREAD MORE…

Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of theREAD MORE…

Gaumard Unveils World’s Most Advanced Pediatric Simulator

MIAMI, Jan. 25, 2018 — A young child may have trouble explaining medical symptoms – yet a quick look at hisREAD MORE…

ProMIS Neurosciences Issues Response to Recent Market Activity

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017 /PRNewswire/ – At the request of IIROC (“Investment Industry Regulatory Organization of Canada“), ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF)READ MORE…

Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology

SAN FRANCISCO, Jan. 22, 2018 ​– Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced the appointment ofREAD MORE…

Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections

SAN DIEGO, Jan. 18, 2018 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needsREAD MORE…

Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma

LEXINGTON, Mass., Jan. 17, 2018 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovativeREAD MORE…

Gaumard Unveils World’s Most Advanced Pediatric Simulator at IMSH ’18

MIAMI, Jan. 12, 2018 /PRNewswire/ — A young child may have trouble explaining medical symptoms – yet a quick look at hisREAD MORE…

Riot Blockchain Establishes Digital Green Energy Corp as New Subsidiary

CASTLE ROCK, Colo., Jan. 9, 2018 /PRNewswire/ — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has establishedREAD MORE…

Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

BERKELEY HEIGHTS, N.J., Jan. 09, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) reviewed itsREAD MORE…

PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities

PTC Therapeutics, Inc. (PTCT) today provided a corporate update, which will be detailed as part of the company’s presentation atREAD MORE…

Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged Living Therapeutics, todayREAD MORE…

Auris Medical Provides Update on AM-111 Development Program

Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, todayREAD MORE…